




Introduction	 The	 high	 molecular	
weight	 of	 methotrexate	 (MTX)	
hinders	 cutaneous	 penetration.	
Oxygen	 flow	 enhances	 cutaneous	
permeation.	 The	 aim	 of	 this	
exploratory	 study	 is	 to	 assess	 the	
clinical	 feasibility,	 efficacy,	 safety	
and	 tolerance	 of	 oxygen	 flow	
administred	 MTX	 (OFAMTX)	 for	
pagetoid	 basal	 cell	 carcinoma	
(PBCC),	 extramammary	 Paget’s	
d isease	 (EMPD)	 and	 mycosis	
fungoides	(MF).	
Material	and	methods	Patients	with	PBCC	
(n=5),	 EMPD	 (n=4),	 classic	 MF	 (n=8)	 and	
folliculotropic	MF	 (n=3)	were	 treated	with	
4	 weekly	 application	 of	 3%	 OFAMTX.	
Photographies	 and	 biopsies	 were	
performed	 before	 (T0)	 and	 one	 month	
after	treatment	(T1).	
Results	 PBCC,	 EMPD	 and	 MF	 responded	
well	to	OFAMTX	with	4/5,	4/4,	7/8	and	1/3	
good	 clinical	 responses	 and	 4/5,	 3/4,	 7/8	
and	0/3	histological	healings,	 respectively.	
Tolerance	was	considered	as	good	and	no	
pain	 was	 observed	 during	 and	 after	
treatment.	 Pharmacokinetics	 never	
revealed	 detectable	 MTX	 levels	 or	 liver,	
renal	 or	 haematological	 alterations	 at	 24,	
48	and	72	hours	post	treatment.	
Conclusion	 OFAMTX	 displays	 a	
potential	 therapeutic	 action	 on	
PBCC,	 EMPD	 and	 MF	 classic	 type	
while	 avoiding	 systemic	 MTX	
related	 adverse	 effects.	 Larger	
cohort	studies	should	be	performed	
to	confirm	these	pilot	data.	
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